Join us for our Abstract Highlights – AACE 2011 Conference – Long Term Effects of Denosumab in Postmenopausal Osteoporosis.

Participants in the 2011 AACE annual meeting considered a report on the long term effects of denosumab in postmenopausal osteoporosis..

Based on their results thus far, the researchers concluded that “5 years of continuous denosumab treatment of postmenopausal women with osteoporosis remained well-tolerated, maintained significant reductions in bone turnover, and continued to increase BMD.”